3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
39
Brain Neoplasms
17
Astrocytoma
16
Central Nervous System Neoplasms
9
Oligodendroglioma
8
Gliosarcoma
8
Melanoma
7
Glioma
7
Neoplasms
5
Recurrence
4
Neoplasm Metastasis
3
Neuroblastoma
2
Ganglioneuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Choroid Plexus Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdoid Tumor
1
Rare Diseases
1
Optic Nerve Glioma
1
Neurotoxicity Syndromes
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Neuroepithelial
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Melanoma, Cutaneous Malignant
1
Interventions
Everolimus
6
lutetium Lu 177 dotatate
5
lanreotide
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Capecitabine
3
surufatinib
2
fluorodopa F 18
2
Introns
2
telotristat ethyl
1
copper dotatate CU-64
1
cabozantinib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Specimen Handling
1
Somatostatin
1
Serotonin
1
Salts
1
Phantoms, Imaging
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Interferon alpha-2
1
Immunoglobulin G
1
Ga(III)-DOTATOC
1
Furosemide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neuroendocrine Tumors
×
Temozolomide
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled